November 11, 2021
Obsidian Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., November 11, 2021 – Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced that Company management will participate in three upcoming investor conferences and include an update on progress with its OBX-115 program:
- Jefferies Global Healthcare Conference (London) | Presenting on Tuesday, November 16, 2021 at 9:20 a.m. GMT | https://wsw.com/webcast/jeff201/obsid/1980846
- Piper Sandler 33rd Annual Virtual Healthcare Conference | Presentations will be available for registered attendees from Monday, November 22, 2021 at 10:00 a.m. ET through December 2, 2021
- RBC Capital Markets Healthcare Private Company Conference | Presenting on Wednesday, December 15, 2021 at 3:50 p.m. ET
OBX-115 is Obsidian’s lead cytoTIL15 program, currently in preclinical development for the treatment of patients with metastatic melanoma and other solid tumors. OBX-115 is a novel engineered tumor infiltrating lymphocyte therapy armed with regulated membrane-bound IL15 that is designed to remove the need for concomitant IL2 therapy, a toxic and costly requirement for conventional TILs. The Company expects to submit an IND for OBX-115 in mid-2022.
About Obsidian Therapeutics
Obsidian Therapeutics, Inc. is a biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology provides a way to precisely control the timing and level of protein function by using FDA approved small molecules. Obsidian is headquartered in Cambridge, Mass. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn and Twitter.
Russo Partners, LLC